بإذنك، نستخدم تحليلات محدودة تراعي الخصوصية لفهم مسارات البحث الفعالة. لا نستخدم أدوات تتبع إعلانية أو تسجيل الجلسات. يمكنك تغيير هذا الخيار في التفضيلات. اقرأ سياسة الخصوصية.
Quote this valuation with its source: Fair value, Potential value and the price at analysis.
FAQ
MDT — frequently asked questions
Is Medtronic plc overvalued?
In our latest published analysis dated 2026-05-12, MDT looks meaningfully undervalued. The price recorded at analysis is 76.8 USD versus our fair value of 95.9 USD; the high endpoint is presented separately as potential value of 114 USD. That implies roughly 24.8% upside to fair value at that date.
Our latest published report, analyzed 2026-05-12, gives MDT a fair value of 95.9 USD and a potential value of 114 USD. The conclusion is triangulated across multiple valuation models and weighted by reliability for Medtronic plc's archetype; it is a dated research output, not a live price.
Should I buy MDT now?
Our latest published rating for MDT, analyzed 2026-05-12, is Buy. Medtronic plc looks meaningfully undervalued at the analysis-date price of 76.8 USD versus fair value of 95.9 USD; potential value is 114 USD. This is research for educational purposes, not personalized investment advice.
What are the biggest risks for MDT?
The dedicated bear-case section in our report analyzed 2026-05-12 documents Medtronic plc's material risks, evidence, thresholds, and thesis-invalidation conditions. Scenario-specific explanations remain in that section so the report does not repeat or decontextualize them elsewhere.
What is MDT's rating?
Our latest published rating for MDT, analyzed 2026-05-12, is Buy, with a published moat assessment of 9/10 (Wide). It reflects our fair value of 95.9 USD, the potential value of 114 USD, and the price recorded at analysis (76.8 USD).
لم تتم ترجمة هذا التقرير بعد. قم بالتحديث خلال بضع دقائق بمجرد أن تلحق قائمة انتظار الترجمة بالركب.
§1 الملخص التنفيذيEN
الإجابة في 30 ثانيةBuy
السعر مقابل القيمة
Price
$76.82
Fair value
$95.89
Potential value
$113.75
As of
تاريخ السعر غير مسجل
لماذا قد تنجح الفرضية
Bull: Successful launch and rapid adoption of new therapies reignite mid-single-digit top-line growth, driving operating leverage and margin expansion.
ما الذي سيغيّر تقييمنا
Pipeline Stagnation: Regulatory and clinical trial setbacks for Cardiovascular and Diabetes pipelines stall product cycles, allowing competitors to permanently seize market share.
Medtronic is a dominant, entrenched player in the global medical devices industry. While near-term growth is sluggish and quarterly earnings are compressed, its immense scale, high switching costs for healthcare providers, and reliable free cash flow easily support a high dividend payout, fitting the classic mature dividend archetype.
Medtronic is a dominant, entrenched player in the global medical devices industry. While near-term growth is sluggish and quarterly earnings are compressed, its immense scale, high switching costs for healthcare providers, and reliable free cash flow easily support a high dividend payout, fitting the classic mature dividend archetype.
Valuation7.5 / 10
Management7.3 / 10
Balance Sheet7.5 / 10
Profitability5.5 / 10
Revenue Growth6 / 10
Risk Assessment8 / 10
Competitive Moat9 / 10
Earnings Quality6 / 10
Capital Efficiency5.5 / 10
Immense scale in the global
Immense scale in the global medical devices industry.
Buy. Medtronic's deeply entrenched portfolio and cash generation capabilities are severely undervalued by a market fixated on near-term trailing stagnation.
نظرة عامة على الشركة
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems and sensors, and InPen, a smart insulin pen. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.
§2 السيناريو الهبوطيEN
A prolonged period of sluggish top-line growth combined with intense pricing pressure and hospital capital constraints severely compresses operating margins below the 19.5% baseline, threatening Medtronic's reliable free cash flow and forcing a cut to its high dividend payout.
Intense competition and pricing pressure erode gross margins, threatening the dividend growth trajectory and resulting in severe multiple compression.
كيف يمكن أن تفشل هذه الأطروحة
Pipeline Stagnation
Medium
Regulatory and clinical trial setbacks for Cardiovascular and Diabetes pipelines stall product cycles, allowing competitors to permanently seize market share.
FV impact
-20%
Trigger
12-24 months
Hospital Capital Freeze
Low
Macroeconomic pressures force severe hospital capital constraints and widespread deferral of elective procedures, crushing revenue growth to negative territory.
إشارات الإنذار المبكر للمراقبة
التطورات الخمسة التي قد تضعف أطروحتنا الاستثمارية.
If revenue growth misses the 1.5% hurdle, shares likely de-rate further; if Cardiovascular and Diabetes post mid-single-digit growth, expect modest multiple expansion toward 14x.
متوافق
Hold
المُحفِّز: In-line results
If revenue growth misses the 1.5% hurdle, shares likely de-rate further; if Cardiovascular and Diabetes post mid-single-digit growth, expect modest multiple expansion toward 14x.
دون التوقعات
Reassess
المُحفِّز: Downside surprise
If revenue growth misses the 1.5% hurdle, shares likely de-rate further; if Cardiovascular and Diabetes post mid-single-digit growth, expect modest multiple expansion toward 14x.
جودة الأرباح
If revenue growth misses the 1.5% hurdle, shares likely de-rate further; if Cardiovascular and Diabetes post mid-single-digit growth, expect modest multiple expansion toward 14x.
Healthcare system capital spending constraints and deferred procedures delay volume recovery.
التموضع
High dividend payout limits aggressive M&A, forcing reliance on internal R&D and pipeline execution.
§11 إدارة المراكزEN
حجم المركز
Core holding given mature dividend archetype and low downside risk.
المخاطر
Re-evaluate if capex/revenue structurally disconnects or if forward revenue estimates drop below 1.5%.
شرائح الدخول
المستوى
إجراء
لماذا
Current / pullbacks
شرائح الخروج
المستوى
إجراء
Thesis break
Re-evaluate if capex/revenue structurally disconnects or if forward revenue estimates drop below 1.5%.
§12 وجهات نظر المستثمرينEN
Bull view
Buy
Buy. The current share price fails to credit the immense durability of Medtronic's free cash flow engine, providing a large margin of safety against sluggish top-line growth.
Base view
Buy
The 1.73% implied growth hurdle from the Reverse DCF confirms extreme market pessimism. Our multi-model synthesis relies heavily on structural cash generation to bypass near-term trailing noise.
§14 التوصية النهائيةEN
إجراء
شراء
Buy. The current share price fails to credit the immense durability of Medtronic's free cash flow engine, providing a large margin of safety against sluggish top-line growth.
Reassess the thesis against the named valuation, risk, and quarterly checkpoint evidence in this report.
§15ملاحظاتك
دوّن أطروحتك الاستثمارية وحجم مركزك وأسئلة المتابعة. تبقى على هذا الجهاز، ولا يراها أحد سواك.
Sub-par capital efficiency indicates that elevated capital outlays are failing to produce accretive operating profits. Generating returns below the corporate hurdle rate erodes economic value and restricts capital redeployment toward high-growth medtech innovations, weakening long-term competitive differentiation.
الحالي:6.6% as of 2026-05-12
تنبيه إذاROIC declines below 5.0% over a twelve-month period
Persistent margin degradation reflects an inability to offset customer pricing pressure and medical inflation through cost containment. Compressing operating margins directly reduces free cash flow generation, eliminating bottom-line operating leverage and endangering the company's valuation multiple relative to peers.
الحالي:19.5% for the period ended 2025-04-30
تنبيه إذاOperating margin falls below 19.5% over two consecutive fiscal quarters
Escalating cash commitment to shareholder payouts leaves little cushion against revenuevolatility or unexpected clinical liabilities. Exceeding sustainable cash boundaries forces either an outright dividend reduction or debt-funded shareholder returns, destroying the core defensive income thesis and triggering severe multiple compression.
Major regulatory or clinical setbacks freeze critical product launch cycles in high-margin growth categories. Failing to refresh innovative offerings allows agile competitors to permanently capture market share, undermining premium pricing power and eliminating key anticipated drivers of mid-single-digit top-line acceleration.
الحالي:Active pipeline development programs as of 2026-05-12
تنبيه إذا1 or more formal FDA rejections or Phase 3 clinical trial terminations in Cardiovascular or Diabetes pipelines within a 12-month period
Monitor
Monitor the threat against the report checkpoints.
Regulatory delays stalling product cycles.
medium
Monitor
Monitor the threat against the report checkpoints.
Warning level: ROIC declines below 5.0% over a twelve-month period. Sub-par capital efficiency indicates that elevated capital outlays are failing to produce accretive operating profits. Generating returns below the corporate hurdle rate erodes economic value and restricts capital redeployment toward high-growth medtech innovations, weakening long-term competitive differentiation.
Warning level: Dividend payout ratio exceeds 90% of free cash flow over an annual period. Escalating cash commitment to shareholder payouts leaves little cushion against revenuevolatility or unexpected clinical liabilities. Exceeding sustainable cash boundaries forces either an outright dividend reduction or debt-funded shareholder returns, destroying the core defensive income thesis and triggering severe multiple compression.
05
المقياس:
Cardiovascular and Diabetes Clinical Approvals
الحاليActive pipeline development programs as of 2026-05-12
لماذا يهم
Warning level: 1 or more formal FDA rejections or Phase 3 clinical trial terminations in Cardiovascular or Diabetes pipelines within a 12-month period. Major regulatory or clinical setbacks freeze critical product launch cycles in high-margin growth categories. Failing to refresh innovative offerings allows agile competitors to permanently capture market share, undermining premium pricing power and eliminating key anticipated drivers of mid-single-digit top-line acceleration.
Boston Scientific CorporationBSX
السعر / القيمة العادلة
القيمة العادلة65.94 US$Report-date price44.51 US$
تاريخ التقييم
الميزة التنافسيةNarrow
بطاقة تقييم الاستثمار72 / 100
Edwards Lifesciences CorporationEW
السعر / القيمة العادلة
القيمة العادلة62.28 US$Report-date price85.71 US$
